Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen

K. Oktay, Erkan Buyuk, O. Davis, I. Yermakova, L. Veeck, Z. Rosenwaks

Research output: Contribution to journalArticle

222 Citations (Scopus)

Abstract

Background: Breast cancer chemotherapy commonly causes premature ovarian failure and infertility. Because increased estrogen levels are thought to be potentially risky in breast cancer patients, natural cycle IVF (NCIVF) has been used to preserve fertility and treat infertility in these women. Methods: Twelve women with breast cancer received 40-60 mg tamoxifen for 6.9 ± 0.6 days beginning on days 2-3 of their menstrual cycle (15 cycles), and had IVF (TamIVF) with either fresh embryo transfer (six cycles) or cryopreservation (nine cycles). They were compared to a retrospective control group (n = 5) who had natural cycle IVF (NCIVF, nine cycles). Results: Cycle cancellation was significantly less frequent in TamIVF, compared with NCIVF (1/15 versus 4/9, P < 0.05). Compared with NCIVF, TamIVF patients had a greater number of mature oocytes (1.6 ± 0.3 versus 0.7 ± 0.2, P = 0.03) and embryos (1.6 ± 0.3 versus 0.6 ± 0.2, P = 0.02) per initiated cycle. TamIVF resulted in the generation of embryo(s) in every patient (12/12) while only three out of five patients had an embryo following NCIVF. Two out of six patients in TamIVF, and 2/5 in NCIVF conceived. One patient in the TamIVF group delivered a set of twins. After a mean follow up of 15 ± 3.6 months (range 3-54), none of the patients had a recurrence of cancer. Conclusions: Tamoxifen stimulation appears to result in a higher number of embryos and may provide a safe method of IVF and fertility preservation in breast cancer patients.

Original languageEnglish (US)
Pages (from-to)90-95
Number of pages6
JournalHuman Reproduction
Volume18
Issue number1
DOIs
StatePublished - Jan 1 2003
Externally publishedYes

Fingerprint

Fertility Preservation
Ovulation Induction
Cryopreservation
Tamoxifen
Embryonic Structures
Breast Neoplasms
Infertility
Primary Ovarian Insufficiency
Embryo Transfer
Menstrual Cycle
Oocytes
Fertility
Estrogens
Recurrence
Drug Therapy
Control Groups

Keywords

  • Breast cancer
  • Fertility preservation
  • IVF
  • Ovarian stimulation
  • Tamoxifen

ASJC Scopus subject areas

  • Physiology
  • Developmental Biology
  • Obstetrics and Gynecology
  • Reproductive Medicine

Cite this

Fertility preservation in breast cancer patients : IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. / Oktay, K.; Buyuk, Erkan; Davis, O.; Yermakova, I.; Veeck, L.; Rosenwaks, Z.

In: Human Reproduction, Vol. 18, No. 1, 01.01.2003, p. 90-95.

Research output: Contribution to journalArticle

Oktay, K. ; Buyuk, Erkan ; Davis, O. ; Yermakova, I. ; Veeck, L. ; Rosenwaks, Z. / Fertility preservation in breast cancer patients : IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. In: Human Reproduction. 2003 ; Vol. 18, No. 1. pp. 90-95.
@article{eb6778a101f6400fbe209483d6be0253,
title = "Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen",
abstract = "Background: Breast cancer chemotherapy commonly causes premature ovarian failure and infertility. Because increased estrogen levels are thought to be potentially risky in breast cancer patients, natural cycle IVF (NCIVF) has been used to preserve fertility and treat infertility in these women. Methods: Twelve women with breast cancer received 40-60 mg tamoxifen for 6.9 ± 0.6 days beginning on days 2-3 of their menstrual cycle (15 cycles), and had IVF (TamIVF) with either fresh embryo transfer (six cycles) or cryopreservation (nine cycles). They were compared to a retrospective control group (n = 5) who had natural cycle IVF (NCIVF, nine cycles). Results: Cycle cancellation was significantly less frequent in TamIVF, compared with NCIVF (1/15 versus 4/9, P < 0.05). Compared with NCIVF, TamIVF patients had a greater number of mature oocytes (1.6 ± 0.3 versus 0.7 ± 0.2, P = 0.03) and embryos (1.6 ± 0.3 versus 0.6 ± 0.2, P = 0.02) per initiated cycle. TamIVF resulted in the generation of embryo(s) in every patient (12/12) while only three out of five patients had an embryo following NCIVF. Two out of six patients in TamIVF, and 2/5 in NCIVF conceived. One patient in the TamIVF group delivered a set of twins. After a mean follow up of 15 ± 3.6 months (range 3-54), none of the patients had a recurrence of cancer. Conclusions: Tamoxifen stimulation appears to result in a higher number of embryos and may provide a safe method of IVF and fertility preservation in breast cancer patients.",
keywords = "Breast cancer, Fertility preservation, IVF, Ovarian stimulation, Tamoxifen",
author = "K. Oktay and Erkan Buyuk and O. Davis and I. Yermakova and L. Veeck and Z. Rosenwaks",
year = "2003",
month = "1",
day = "1",
doi = "10.1093/humrep/deg045",
language = "English (US)",
volume = "18",
pages = "90--95",
journal = "Human reproduction (Oxford, England)",
issn = "0268-1161",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Fertility preservation in breast cancer patients

T2 - IVF and embryo cryopreservation after ovarian stimulation with tamoxifen

AU - Oktay, K.

AU - Buyuk, Erkan

AU - Davis, O.

AU - Yermakova, I.

AU - Veeck, L.

AU - Rosenwaks, Z.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Breast cancer chemotherapy commonly causes premature ovarian failure and infertility. Because increased estrogen levels are thought to be potentially risky in breast cancer patients, natural cycle IVF (NCIVF) has been used to preserve fertility and treat infertility in these women. Methods: Twelve women with breast cancer received 40-60 mg tamoxifen for 6.9 ± 0.6 days beginning on days 2-3 of their menstrual cycle (15 cycles), and had IVF (TamIVF) with either fresh embryo transfer (six cycles) or cryopreservation (nine cycles). They were compared to a retrospective control group (n = 5) who had natural cycle IVF (NCIVF, nine cycles). Results: Cycle cancellation was significantly less frequent in TamIVF, compared with NCIVF (1/15 versus 4/9, P < 0.05). Compared with NCIVF, TamIVF patients had a greater number of mature oocytes (1.6 ± 0.3 versus 0.7 ± 0.2, P = 0.03) and embryos (1.6 ± 0.3 versus 0.6 ± 0.2, P = 0.02) per initiated cycle. TamIVF resulted in the generation of embryo(s) in every patient (12/12) while only three out of five patients had an embryo following NCIVF. Two out of six patients in TamIVF, and 2/5 in NCIVF conceived. One patient in the TamIVF group delivered a set of twins. After a mean follow up of 15 ± 3.6 months (range 3-54), none of the patients had a recurrence of cancer. Conclusions: Tamoxifen stimulation appears to result in a higher number of embryos and may provide a safe method of IVF and fertility preservation in breast cancer patients.

AB - Background: Breast cancer chemotherapy commonly causes premature ovarian failure and infertility. Because increased estrogen levels are thought to be potentially risky in breast cancer patients, natural cycle IVF (NCIVF) has been used to preserve fertility and treat infertility in these women. Methods: Twelve women with breast cancer received 40-60 mg tamoxifen for 6.9 ± 0.6 days beginning on days 2-3 of their menstrual cycle (15 cycles), and had IVF (TamIVF) with either fresh embryo transfer (six cycles) or cryopreservation (nine cycles). They were compared to a retrospective control group (n = 5) who had natural cycle IVF (NCIVF, nine cycles). Results: Cycle cancellation was significantly less frequent in TamIVF, compared with NCIVF (1/15 versus 4/9, P < 0.05). Compared with NCIVF, TamIVF patients had a greater number of mature oocytes (1.6 ± 0.3 versus 0.7 ± 0.2, P = 0.03) and embryos (1.6 ± 0.3 versus 0.6 ± 0.2, P = 0.02) per initiated cycle. TamIVF resulted in the generation of embryo(s) in every patient (12/12) while only three out of five patients had an embryo following NCIVF. Two out of six patients in TamIVF, and 2/5 in NCIVF conceived. One patient in the TamIVF group delivered a set of twins. After a mean follow up of 15 ± 3.6 months (range 3-54), none of the patients had a recurrence of cancer. Conclusions: Tamoxifen stimulation appears to result in a higher number of embryos and may provide a safe method of IVF and fertility preservation in breast cancer patients.

KW - Breast cancer

KW - Fertility preservation

KW - IVF

KW - Ovarian stimulation

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=0037247939&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037247939&partnerID=8YFLogxK

U2 - 10.1093/humrep/deg045

DO - 10.1093/humrep/deg045

M3 - Article

C2 - 12525446

AN - SCOPUS:0037247939

VL - 18

SP - 90

EP - 95

JO - Human reproduction (Oxford, England)

JF - Human reproduction (Oxford, England)

SN - 0268-1161

IS - 1

ER -